| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1998PNAS...9514411Q |
| P356 | DOI | 10.1073/PNAS.95.24.14411 |
| P932 | PMC publication ID | 24387 |
| P698 | PubMed publication ID | 9826714 |
| P5875 | ResearchGate publication ID | 13459447 |
| P2093 | author name string | J M Wilson | |
| A Davis | |||
| X Q Qin | |||
| N Tao | |||
| P Moy | |||
| J Barsoum | |||
| S Fawell | |||
| A Dergay | |||
| P2860 | cites work | Selective expression of an interleukin-12 receptor component by human T helper 1 cells | Q24670175 |
| Biochemistry of Interferons and Their Actions | Q28262345 | ||
| Human interferon omega (omega) binds to the alpha/beta receptor | Q28272866 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Growth of human hepatoma cells lines with differentiated functions in chemically defined medium | Q29617962 | ||
| Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas | Q34344877 | ||
| The role of angiogenesis in tumor growth | Q34539790 | ||
| Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver | Q35559973 | ||
| 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data | Q36435390 | ||
| Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review | Q36574740 | ||
| Mechanisms of Endothelial Growth Control | Q36729305 | ||
| Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy | Q37642230 | ||
| Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta | Q40794190 | ||
| p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer | Q40973708 | ||
| In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. | Q41068483 | ||
| Why do so many cancer patients fail to respond to interferon therapy? | Q41480595 | ||
| Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta | Q41609229 | ||
| Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. | Q41657338 | ||
| Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity | Q41719324 | ||
| Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response | Q41744259 | ||
| Murine interleukin-4 displays potent anti-tumor activity in vivo | Q42816834 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| Interferon-beta is required for interferon-alpha production in mouse fibroblasts | Q43412872 | ||
| Mouse interferon receptors: a difference in their response to alpha and beta interferons | Q43957898 | ||
| Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity | Q45091285 | ||
| Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. | Q45870000 | ||
| IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. | Q45871212 | ||
| Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models | Q45884874 | ||
| Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene | Q45887885 | ||
| Induction of bystander T cell proliferation by viruses and type I interferon in vivo | Q46486509 | ||
| Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. | Q52488991 | ||
| The human interferon alpha-receptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants. | Q54200731 | ||
| Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. | Q54400192 | ||
| Various human interferon a subclasses cross-react with common receptors: Their binding affinities correlate with their specific biological activities | Q70188498 | ||
| Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells | Q70577067 | ||
| The neglected role of type I interferon in the T-cell response: implications for its clinical use | Q71475326 | ||
| Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers | Q71763735 | ||
| Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma | Q71763737 | ||
| IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice | Q72427870 | ||
| Injection of irradiated b16 melanoma genetically-modified to secrete IFN-alpha causes regression of an established tumor | Q84066152 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 14411-14416 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice | |
| P478 | volume | 95 |
| Q38357901 | A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response |
| Q64376835 | A phase I trial of Ad.hIFN-beta gene therapy for glioma |
| Q37301637 | AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models |
| Q39132762 | Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers |
| Q36866472 | Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β. |
| Q43412741 | Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma |
| Q45879102 | Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q39298919 | Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts |
| Q37088489 | Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas |
| Q42574280 | Anti-colorectal cancer effect of interleukin-2 and interferon-β fusion gene driven by carcinoembryonic antigen promoter |
| Q45868391 | Anti-inflammatory action of type I interferons deduced from mice expressing interferon beta. |
| Q40314573 | Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer |
| Q54337036 | Calcineurin subunit B upregulates β-interferon production by phosphorylation of interferon regulatory factor 3 via Toll-like receptor 4. |
| Q92549179 | Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes |
| Q39963975 | Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs |
| Q40771354 | Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma |
| Q44393120 | Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q34547126 | Foot-and-mouth disease |
| Q34452062 | Gene therapy for high grade gliomas |
| Q35673628 | Gene therapy for malignant glioma |
| Q36786243 | Gene therapy in the treatment of heart failure |
| Q35024674 | Gene therapy of neoplastic liver diseases. |
| Q40309654 | Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors |
| Q42135456 | Gene- and viral-based therapies for brain tumors |
| Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
| Q35786848 | Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response |
| Q39354078 | Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells |
| Q39306638 | Interferon-β-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells |
| Q33804926 | Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis |
| Q44796636 | Long-term high-dose interferon-α therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice |
| Q24612339 | Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model |
| Q35917287 | New approaches to rapidly control foot-and-mouth disease outbreaks |
| Q39699303 | Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease |
| Q24605512 | Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q38517215 | Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth |
| Q45886750 | Secretion polarity of interferon-beta in epithelial cell lines |
| Q37404242 | Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b. |
| Q37420576 | Strategies in gene therapy for glioblastoma. |
| Q44194187 | Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide |
| Q36167296 | Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases |
| Q92003161 | Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy? |
| Q50083504 | Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas. |
| Q98771952 | Use of IFN-Based Biotherapeutics to Harness the Host Against Foot-And-Mouth Disease |
Search more.